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Abstract 
 
Aims: The literature on fever related arrhythmic events (AE) in Brugada syndrome (BrS) 
patients is currently limited to few case reports and small series.  
The current study aims to describe the characteristics of fever-related AE in a large cohort of BrS 
patients.  
Methods and Results: SABRUS is a multicenter study that gathered data from 678 BrS patients 
with first AE documented at time of aborted cardiac arrest (CA) (n=426) or after prophylactic 
ICD implantation (n=252). In 35(6%) of the 588 patients with available information, the AE 
occurred during a febrile illness.  
Most of the 35 patients were male (80%), Caucasian (83%) and proband (70%). Age at time of 
AE was 29±24 (range 0.3-76) years. Most patients (80%) presented with aborted CA and 6 
(17%) with arrhythmic storm. Family history of sudden death, history of syncope and 
spontaneous type 1 Brugada-ECG were noted in 17%, 40% and 66% of patients, respectively. 
VF was induced at EPS in 9/19(47%) patients. An SCN5A mutation was found in 14/28(50%) 
patients. The highest proportion of fever-related AE was observed in the pediatric population 
(age <16), especially the very young (0-5 years old) (67%). Males were involved in all age 
groups and females only in the pediatric and elderly groups. Fever-related AE affected 17 
Caucasians aged <24 years, but no Asians aged <24 years.    
Conclusions: The risk of fever-related AE in BrS markedly varies according to age group, 
gender and ethnicity. Taking these factors into account could help the clinical management of 
BrS patients with fever.  
Key words: Fever, Brugada syndrome, children, elderly, gender, ethnicity 
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Brugada syndrome (BrS) is an inherited disease that predisposes to sudden cardiac death (SCD), 
striking mainly males aged 27-59 years old1. Risk factors for malignant ventricular arrhythmias 
during follow-up include: a previous history of aborted SCD or malignant syncope, and inducible 
ventricular fibrillation (VF) at electrophysiological study (EPS)2, 3, spontaneous type 1 Brugada-
ECG4, ECG markers of QRS fragmentation5, 6 and prominent S wave in lead 17. In addition, 
several factors are known to precipitate an arrhythmic event (AE) in BrS  patients such as  
specific drugs8, increase in vagal tone9 and fever10. 
The SCN5A-encoded α-subunit of the NaV1.5 cardiac sodium channel has been linked to BrS 
and mutations in SCN5A are identified in 14–26% of BrS cases11. Dumaine et al.12 were the first 
to link temperature with the function of a mutant SCN5A sodium channel. Later it was 
demonstrated that fever may induce type 1 ECG in BrS patients13. Two large studies 
demonstrated that in unselected populations with fever, type 1 Brugada-ECG may be seen in 2-
4% of patients14, 15 but none of these patients experienced malignant AE’s. However, Mizusawa 
and colleagues16 recently demonstrated that, as opposed to patients who have only drug 
challenge induced type 1 ECG, those with fever-induced type 1 ECG (F-type 1) have an 
increased risk for symptomatic disease including syncope and VF. Likewise, there are only few 
case reports and small series describing patients with BrS and proven fever-related AE. The 
Survey on Arrhythmic events in BRUgada Syndrome (SABRUS) is a multicenter study that 
collected data on the first AE in 678 patients with BrS1. The objective of the present study was to 
describe the characteristics of patients with fever-related AE in this large SABRUS patient 
cohort.  
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Methods 
The study was approved by the Tel Aviv Medical Center Institutional Review Board committee. 
The 678 SABRUS patients originated from 23 centers in 10 Western and 4 Asian countries1. 
Sixteen (69.5%) centers provided data from their institution only, whereas the remaining 7 
(31.5%) provided data from multiple institutions from their countries. 
Data acquisition. Study inclusion criteria consisted of 1) a typical type 1 Brugada-ECG either 
spontaneously or following the intravenous administration of a cardiac sodium channel blocking drug; 
2) a first documented AE (sustained ventricular tachyarrhythmia). Anonymous patient information 
was collected using a predefined questionnaire regarding the following: 1) whether or not the AE was 
associated with fever; 2) age at the time of the first AE; 3) mode of AE documentation (group A or 
group B, see below);  4) gender; 5) proband status; 6) ethnicity (Caucasian, Asian, other or unknown);  
7) family history of SCD;  8) prior history of syncope ; 9) presence of spontaneous or drug-induced 
type 1 Brugada-ECG; 10) inducibility of VF at EPS and 11) presence of SCN5A mutation.  
Definitions. The patients were classified in 2 groups according to the mode of AE documentation:  
- Group A: Patients with documented aborted CA in whom the BrS-diagnosis was made during work-
up performed after CA. 
- Group B: Patients with a BrS-diagnosis in whom prophylactic ICD implantation was performed for 
any reason and in whom an AE requiring appropriate ICD therapy was documented during follow-up 
by ICD interrogation.    
Proband status: Proband was defined as the first patient of a family who has been diagnosed with the 
type-1 Brugada-ECG (spontaneous or drug-induced). A non-proband was defined as a family member 
of a known BrS-patient.   
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Age groups: For analyzing the effect of age on fever-related AE, patients were divided into 8 
age categories: 1) early childhood: 0-5 years; 2) late childhood: 6-15 years; 3) adult life: 16-70 
years, divided in 5 equal bins of 11 years; 4) elderly: age >70 years old. 
Model for predicting the risk of AE per day of fever. In order to predict the risk of AE per day of 
fever (day at risk) in each age group a model which took in account the data provided by all 23 main 
centers participating in SABRUS was built. These centers were invited to participate in a registry by 
providing the age and gender distribution of the entire BrS population followed at their own center 
(with or without prior AE). The centers from Western and Asian countries were assumed to include 
Caucasian and Asian patients, respectively, based on SABRUS results showing that only 1.7% of the 
patients from Western countries had an Asian origin while no patient from Asian countries was 
Caucasian1.    
The Delphi method 17 was used in order to estimate the average number of fever days per year in 
the 8-different age groups. Briefly, 10 physicians (5 experts in adult internal medicine and 5 
experts in pediatrics) were contacted separately by e-mail. They were asked to give an estimation 
of the average fever days in each age group in a step wise approach; first, they were blinded of 
the estimations given by other participants. Before the second and third tours the average of the 
10 answers given for each age group was sent to the participants and they were allowed to 
change their answer accordingly.  
As the exact birth date of the patients was unknown the model assumed the AE occurred at the 
middle of the year (after 6 months) and therefore the days at risk (or days with fever) for patients 
with an AE were assumed to be half of the estimation provided by the Delphi method 
The event per day at risk was calculated as =
𝑇ℎ𝑒 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑒𝑣𝑒𝑛𝑡𝑠 𝑝𝑒𝑟 𝑡ℎ𝑒 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑎𝑔𝑒 𝑔𝑟𝑜𝑢𝑝
𝐷𝑎𝑦𝑠 𝑎𝑡 𝑟𝑖𝑠𝑘 
 
While days at risk for the specific age group = 
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= 𝑁𝑜.  𝑜𝑓 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝐴𝐸 ∗ 𝑓𝑒𝑣𝑒𝑟 𝑑𝑎𝑦𝑠 𝑝𝑒𝑟 𝑦𝑒𝑎𝑟 +  𝑁𝑜. 𝑜𝑓 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠 𝑤𝑖𝑡ℎ 𝐴𝐸 ∗ 𝑓𝑒𝑣𝑒𝑟 𝑑𝑎𝑦𝑠 𝑝𝑒𝑟 𝑠𝑖𝑥 𝑚𝑜𝑛𝑡ℎ.  
The 95% CI for the “event per day at risk” was calculated using the WINPEPI computer 
program18. 
Statistical analysis. 
Assumptions of normality of the different ages were assessed by Kolmogorov–Smirnov test and Q-Q 
plots. Differences between non-normally distributed ages were assessed using a Mann–Whitney U 
test. Ratio differences were examined by a Chi-square test or a Fisher's exact test as appropriate. 
Statistical significance was defined as P<0.05. Scale variables are presented as Median [IQR] for 
when not normally distributed. All calculations were performed using SPSS version 24 (IBM, 
Armonk, NY, USA).  
Results 
Study patient cohort.  
SABRUS gathered 678 BrS patients with first AE, including 588 (86.7%) patients in whom there 
was information available on a possible relationship between AE and fever. In 35 (5.95%) of 
these 588 patients, the AE occurred during a febrile illness. These 35 patients comprised the 
study group.  
Characteristics of patients with fever-related AE. 
The characteristics of the 35 patients with AE associated with fever are presented in Table 1.  Of 
note, the vast majority (n=32) of these patients provided from the main SABRUS centers while 
only 3 provided from subsidiary medical centers.  
Most patients were male (28 of 35, 80%) and Caucasian (29 of 35, 83%) with a mean age of 
29±24 (range 0.3-76) years at the time of AE. The vast majority (28 of 35, 80%) presented with 
aborted CA (group A) while the remaining patients belonged to group B.  Six (17%) patients 
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presented with VF storm. Most patients were probands (70%). A family history of SCD and a 
history of syncope were noted in 17% and 40% of patients, respectively.  A spontaneous type 1 
Brugada-ECG was observed in 24 (66%) of patients. VF was induced at EPS in 9 (47%) of the 
19 patients who underwent the procedure. An SCN5A mutation was found in 14 (50%) of the 28 
patients who underwent genetic testing.  
Comparison between patients with or without fever-related AE. 
The age distribution was markedly different in the 2 patient groups (Fig. 1A). In the study group, 
13 (37.1%) of the 35 AE occurred in the pediatric population (age <16 years) especially in the 
very young (<5 years) (11 of 13, 84.6%); the AE occurred between ages 16-70 in 20 (57.1%) 
patients and after age 70 in 2 (5.7%) patients (Fig. 1A). In contrast, in the patients with AE not 
related to fever, the AE mainly occurred (96%) between 16-70 years and rarely in the pediatric 
and elderly age groups (2.9% and 1.1%), respectively (P< 0.001) (Fig. 1A).  When analyzing the 
percentage of patients with fever-related AE in regard to the total number of patients with AE in 
SABRUS, the highest AE rate was observed during early childhood (age 0-5, 65%), followed by 
a marked decline during late childhood (age 6-15, 16.7%) and adulthood (age 16-70, 3.6%) with 
a subsequent marked rise to 25% in the elderly (Fig. 1A).  
Comparisons between patients with and without fever-related AE are presented in Table 2.  
Patients with fever-related AE had a lower proportion of males (80% vs. 92%, P=0.03) and 
probands (70% vs. 87%, P=0.02). In contrast, they were more likely to be younger at time of AE 
[median age (IQR) of 25 (3-46) vs. 43 (34-52), P<0.001)], to belong to Group A (80% vs. 59%, 
P=0.02), to be Caucasian (83% vs. 56%, P=0.007) and to be SCN5A mutation carriers (50% vs. 
31%, P=0.04). 
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Other variables including family history of SCD, history of syncope, positive EPS, spontaneous 
type 1 Brugada-ECG and presentation with an arrhythmic storm were not significantly different 
among the 2 groups.  
Comparison between males and females with fever-related AE.  
Comparisons between males and females with fever-related AE are presented in Table 3A. 
Females with fever-related AE were younger [(median age (IQR) of 3 (0.4-16) vs. 35.5 (7.25-
46.75), P=0.04]. The age distribution of males and females and the percentage of fever-related 
AE at different age groups are presented in Figure 1B. As shown, all fever-related AE in females 
were censored from early childhood until age of 16 with no other cases during adulthood except 
for a single 70-year old female. In contrast fever-related AE in males occurred in all age groups.  
The rate of fever-related AE tended to be higher in female patients aged <26 years as compared 
to males in the same age group (43% vs. 16.7%, P=0.065). Another difference between males 
and females concerned the EPS response. An inducible arrhythmia was observed in 64% of 
tested males but in none of the females (P=0.03). Other analyzed variables were not gender 
specific.  
Comparison between children (age <16) and adults (age >16) with fever-related AE.                                                        
This comparison is presented in Table 3B. There was a tendency toward a higher percentage of 
females (38% vs. 9%, P=0.08) and Caucasians (100% vs. 73%, P=0.06) among children with 
fever-related AE as compared to adults. An SCN5A mutation was significantly more frequently 
observed in children (77% vs. 27% in adults, P=0.008). Other variables including mode of AE 
presentation, proband status, family history of SCD, history of syncope, spontaneous type 1 
Brugada-ECG, inducible arrhythmia at EPS and VF storm were not different between children 
and adults.  
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Comparison between Caucasians and Asians with fever-related AE.  
This comparison is presented in Table 3C. Caucasians tented to be younger than Asians [median 
age (IQR) of 22 (3-45) vs. 42 (31-61), P=0.05]. Among the patients with fever-related AE, there 
were 17 Caucasians aged <24 years old including 11 patients aged <5 years whereas the younger 
Asian patient was 25 years old. Caucasians tended to exhibit a spontaneous type 1 Brugada-ECG 
(P=0.06). The other variables tested were not significantly different in respect to patient 
ethnicity.   
Estimation of arrhythmic risk for 1000 fever days. 
Twenty-two of the 23 main SABRUS centers provided the age and gender distribution of the 
entire BrS population followed at their own center (with or without prior AE). The registry 
comprised 6441 patients (73.4% males, 88% Caucasians) including 500 patients with and 5941 
without AE. Of note, the other 178 SABRUS patients who were not followed by the main 
participating centers and in whom the denominator from which these patients were collected was 
unknown, were not included in the present sub-analysis. In 77 of the 500 SABRUS patients, 
there was no information available about the possible association of fever with AE and therefore 
these 77 patients were also excluded from further analysis. A flowchart describing patient 
selection is presented in Figure 2. As shown, overall 32 patients had and 6332 patients did not 
have fever-related AE.   
The age-group distribution of the patients with and without fever-related AE is presented in table 
4, demonstrating that 70.9% of the BrS population were 27-59 years old. This table also denotes 
the estimated yearly fever days from the Delphi method. As shown, the estimated average fever 
days per year of children aged 0-5 was 2.6-3.7 times higher compared to age categories ranging 
from 16-70 years old and 1.7-1.8 times higher compared to age groups 6-15 and >70. Figure 3 
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demonstrates the estimated AE rate per 1000 fever days according to the specific age group. It 
shows an estimated rate of 14.8 AE (95% CI 7.4, 26.3) per 1000 fever days in BrS patients aged 
0-5 years old with similar rates between females and males. In contrast, the estimated AE rate 
dropped to 0.33-2.5 events per 1000 fever days in all other age groups.  
Discussion 
Main findings.  
The present study describes the largest series ever reported of BrS patients with fever-related 
AE.  It shows that ≈ 6% of AE in BrS were associated with fever. These AE mainly occurred in 
Caucasians males, in all age groups and often with a presentation of aborted CA.  The highest 
proportion of fever-related AE was observed in the pediatric population (age <16), especially the 
very young (0-5 years old). Marked gender differences were noted with involvement of males in 
all age groups contrasting with exclusive female involvement in the pediatric and elderly groups. 
Fever-related AE did not involve any Asian patient aged <25 years old. Also, the youngest 
patient group (age 0-5) exhibited the highest estimated rate of AE per 1000 fever days in the BrS 
population, with similar rates between males and females.  
Prior reports on fever-related AE. 
Table 5 summarizes all previous publications of fever-related AE in BrS comprising 40 patients 
in 22 reports. Only 4 (18%) of the 22 reports included patients (n=9) who originated from Asian 
countries. Careful analysis of these publications, as well as contact with the respective authors, 
enabled us to confirm that up to 15 cases included in SABRUS had been already published, 
however with very limited data that did not include age and gender in most of them10, 19, 20. The 
largest report includes 7 patients19 while 16 (72%) of these 22 publications dealt with case 
reports. Age and gender were provided for 18 (45%) and 23 (57%) patients, respectively. Male 
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involvement was observed in all age groups; however, there were 8 females with fever induced 
AE at very young age (<2 years, n=6) or after menopause (>50 years, n=2). ECG data was 
provided on 18 patients (45%) showing spontaneous type 1 Brugada-ECG in 8 (44%). Thirteen 
out of 19 tested patients (68%) had SCN5A mutations. EPS was performed in 4 patients and was 
positive in all of them. 
Brugada and fever. 
Two studies examined the prevalence of fever induced Brugada pattern (F-type 1) among febrile 
patients referred to the emergency department. Adler et al.14 reported a prevalence of 2%, while 
Rattanawong et al.15 who conducted their study in an endemic area found a higher 4% 
prevalence. The latter, which is 20 times more than the known prevalence of BrS in the general 
population21, 22, suggests that fever induced Brugada-ECG changes are benign. Indeed, none of 
the patients in these 2 studies developed an AE during follow up. However, Mizusawa et al.16 
found that among 88 asymptomatic patients at baseline who developed F-type 1 Brugada-ECG, 3 
(3.4%) developed an AE including 1 which was fever-related. The AE event rate in these 88 
asymptomatic patients was 0.9%/year i.e. similar to the event rate in patients with spontaneous 
type 1 (0.5-0.8% /year) and higher than the event rate in patients with drug-induced type 1 ECG 
(0-0.35%/year)16. Thus, Mizusawa et al.16 suggested that the occurrence of F-type 1 is probably a 
sign of poorer prognosis, yet it by no means implies that the risk for AE is present only or mainly 
during fever. 
Gender and fever-related AE.  
In the total SABRUS population of 678 patients with AE, females accounted for 8.7% of the 
population which exhibited ales involved 20% of the . In the present study, however, fem1cohort
fever-related AE.  
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One possible explanation for this apparent higher propensity of females to develop fever-related 
AE deals with the higher SCN5A mutation rate observed in patients with fever-related AE (50% 
vs. 31% in those without fever-related) (Table 2), especially in females (80% vs. 43% in males) 
(Table 3A).  In this scenario, one could hypothesize on a more proarrhythmic effect of fever in 
mutation carriers.  
Another interesting finding of our study was the exclusive occurrence of AE in females at 
childhood or the elderly while this occurred at all age groups in males. This was also observed by 
others (see Table 5) and suggests an “antiarrhythmic protection” in females during their 
reproductive period. Several theories were raised regarding the protective role of female gender 
on disease manifestation including: gender differences in ionic currents23 and the effect of sex 
hormones24. Thus, one may speculate that estrogen and not the absence of testosterone is the 
main protector against fever-related AE in females during their reproductive period.  
Children and fever-related AE. 
Children (age <16 years) represented a considerable proportion of patients with fever-related AE 
(37.1%) despite they comprised only 4.3% the total SABRUS population1. We found that 
children of both genders exhibited a considerable risk of fever-related AE as compared with 
patients in all other age groups. AE were related with fever in 67% and 16.7% of patients aged 0-
5 and 6-15, respectively, while this was the case in only 3.9% of those patients aged >16 years. 
Previous studies 25, 26 suggested a higher risk of fever-related symptoms in children; however 
most described episodes of syncope and not a proven AE26, 27. As children have more febrile 
illnesses compared to adults it was speculated that a greater risk exposure may lead to this high 
rate of fever-related symptoms26. However, when taking into account both total BrS population 
and the average yearly fever days in each age group we found that the risk of AE in a 
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comparable risk exposure (i.e. 1000 fever days) is much higher only among children aged 0-5 
years compared to any other group. On the other hand, the higher event rate in children aged 6-
15 may be related to more fever days with similar event rate per 1000 fever days as adults. The 
exact mechanism of this cluster of event in ages 0-5 is unknown and should be further 
investigated. Nevertheless, it has clinical implications as discussed below.  
Another interesting finding of the present study was the higher rate of SCN5A mutation in 
children with fever-induced AE (77%) as compared to adults (27%) (P=0.02). The significance 
of this very high mutation rate should be interpreted with caution since our study was not 
powered to determine whether BrS children without SCN5A mutation have lower risk of AE 
during fever. Nevertheless, significantly lower mutation rates (59 of 201, 29.3%, P=0.001) were 
found in children without previous documented AE aged <16 years (Andorin and Probst, 
Sarquella-Brugada, Giustetto and Conte, personal communication, 2017). Therefore, it is 
possible that the presence of SCN5A mutation in children may indicate a higher arrhythmic risk 
during fever.   
Elderly and fever-related AE. 
AE’s in the elderly population (>70 years) with BrS are rare, accounting for 1% of cases of AE 
in 678 SABRUS patients. The paucity of AE in the elderly was also reported by others28-30.  
However, we found a 25% rate of fever-related AE in the 70+ age group. Yet, when taking into 
account the total BrS population and fever days, which are estimated to be higher than in adults 
(age<70), the estimated risk of AE per 1000 fever days was not significantly different from other 
age groups except from early childhood. Thus, it seems that the risk of AE in the elderly is 
similar to adults. Larger studies in the elderly group are needed to confirm our findings.   
Ethnicity and fever-related AE.  
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There were 2 main differences between Caucasians and Asians with regard to fever-related AE. 
First, Caucasians predominated much more in the fever-related AE group than in the afebrile-
related AE group. Secondly, Asians with fever-related AE were much older and the youngest in 
our cohort was 25 years old. A review of the literature (Table 5) confirms the extreme rarity of 
the involvement of Asians in fever-related AE, especially in children, with a single report of 
rapid monomorphic VT in a 2.2 year-old Korean child31. The lower risk for fever-related AE in 
Asian children may suggest that their mutation is sensitive to testosterone, which absence during 
childhood may also protect from the effect of fever. Further research is needed to explore this 
possibility.  
Clinical implications. 
Our results demonstrate that fever-related AE is the first manifestation of the disease in the 
majority of patients and may occur in a substantial number of previously asymptomatic patients 
without spontaneous type 1 Brugada-ECG. Therefore, in accordance with the current 
guidelines32, aggressive antipyretic therapy should be administered to any BrS patient with fever. 
In addition, special attention should be provided to those children (especially those aged 0-5 
years) with syncope and/or febrile seizures who should undergo ECG to exclude the possibility 
of transient BrS-related AE33.  A survey conducted among pediatric electrophysiologists found 
that only 3% of them recommend admission for observation of BrS children with fever 34. Our 
findings suggest that a policy of lower threshold for in-hospital observation should be adopted in 
children, especially in Caucasians aged < 5 years. However, based on our present study and prior 
reports, the risk of AE of any type (fever-related or not) in Asian children seems to be extremely 
low allowing to recommend a more liberal hospitalization policy. Moreover, our data suggest 
that the presence of SCN5A mutation in children may indicate a higher arrhythmic risk during 
17 
 
 
fever.  Finally, BrS females at their reproductive age also have a very low AE risk and can be 
managed conservatively with antipyretics at outpatient settings, unless any alarming symptoms 
occur.  
Limitations. 
Not all SABRUS patients were followed by the participating centers and the denominator from 
which these patients were collected was unknown. Yet, even if these 178 patients had been 
excluded the results demonstrated in Tables 2-3 would not change meaningfully (Supplemental 
tables 1-2), thus minimizing the possibility of a bias.  The study is retrospective and details 
regarding whether the patients had type 1 Brugada-ECG changes during fever (F-type 1) were 
not available, precluding the analysis of  F-type ECG changes as a risk factor for AE. Our model 
of AE event risk per 1000 fever days is based on a calculated estimation of 10 experts since we 
do not know the exact risk exposure (fever days) of our BrS population. Finally, the number of 
females and elderly patients is limited and larger cohorts of these subgroups are needed.  
Conclusions 
Around 6% of AE in BrS patients are associated with fever. The risk of fever-related AE in BrS 
markedly varies according to age group, gender and ethnical origin of patients. Taking these 
factors into account may help in the clinical management of BrS patients with fever. 
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Figure legends 
Figure 1A:  Patient age distribution. Patients with (left panel) or without (middle panel) fever-
related AE are shown. The percentage of patients with fever-related AE in each age group is 
presented on the right panel. The highest percentage of fever-related AE is observed during 
childhood (0-15 years) with another rise in percentage in the elderly (age >70) 
Figure 1B: Age distribution in males and females. Patients with (left panel) or without (middle 
panel) fever-related AE are shown. The percentage of patients in each gender with fever-related 
AE in each age group is presented on the right panel. Since the only females in age groups 16-26 
and 60-70 were 16 and 70 years old, respectively, there are no cases of females with fever-
related AE between ages 17-69.  
Figure 2: Flowchart. Flowchart describing total BrS patient population and how patients were 
divided into subgroups with and without fever-related AE (see text).   
Figure 3: Estimated arrhythmic event rate per 1000 fever days in each age group. The 
circles represent the estimated rate and the whiskers represent the 95% CI. The estimated risk in 
children aged 0-5 is higher than any other group in both genders. When looking at the estimated 
event rate of all patients (marked in black), there is no overlap of any estimation including its 
95% CI with that of 0-5 years old age group.  
 
 
